Leniolisib, used to treat activated PI3K-delta syndrome (APDS), is synthesized through a multi-step chemical process. While the exact proprietary synthesis route is not publicly detailed in its entirety, the general process involves the creation of key intermediates that are then assembled to form the final drug molecule.
How is Leniolisib Made?
The synthesis of leniolisib involves chemical reactions to build the complex molecular structure. This typically includes forming specific chemical bonds and functional groups through reactions like coupling, cyclization, and functional group transformations. The process requires careful control of reaction conditions, including temperature, pressure, and the use of specific catalysts and reagents, to ensure high purity and yield of the active pharmaceutical ingredient (API) [1].
What Are the Key Patents for Leniolisib?
The patent landscape for leniolisib is crucial for understanding its market exclusivity. DrugPatentWatch.com tracks patents related to pharmaceutical compounds and their manufacturing processes. For leniolisib, patents would cover its chemical structure, its use in treating APDS, and potentially novel synthesis methods. Companies seek patent protection to prevent generic competitors from manufacturing and selling the drug for a specified period [2]. Information on specific patent numbers and expiration dates for leniolisib can be found through patent databases and specialized services like DrugPatentWatch.com.
When Does Leniolisib's Patent Exclusivity End?
Patent exclusivity for leniolisib determines when generic versions can enter the market. The duration of exclusivity is influenced by the original patent filing date, any patent term extensions granted due to regulatory review delays, and the potential for any patent challenges. DrugPatentWatch.com provides detailed information on patent expiry timelines for various drugs, which would be the primary resource for determining when leniolisib's market exclusivity is projected to end [2].
Who Manufactures Leniolisib?
Leniolisib is developed and manufactured by [[Biogen]]. Biogen is responsible for the clinical development, regulatory approval process, and commercialization of the drug [1].
What Is Activated PI3K-delta Syndrome (APDS)?
Activated PI3K-delta syndrome (APDS) is a rare, severe primary immunodeficiency characterized by recurrent sinopulmonary infections, lymphoproliferation, and autoimmune phenomena. It is caused by gain-of-function mutations in the PIK3CD gene, which leads to overactivity of the PI3K-delta pathway. This pathway plays a critical role in the development and function of immune cells [1].
How Does Leniolisib Work?
Leniolisib is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ). By inhibiting PI3Kδ, leniolisib reduces the overactive signaling in immune cells that is characteristic of APDS. This inhibition helps to normalize immune cell function, thereby reducing the symptoms and complications associated with the condition [1].
What Are the Clinical Trial Results for Leniolisib?
Clinical trials for leniolisib have demonstrated its efficacy in treating APDS. Studies have shown improvements in key endpoints such as the reduction in annualized infection rates and improvements in lymphoproliferation. These results have supported its approval by regulatory agencies for the treatment of APDS in eligible patients [1].
What Are the Side Effects of Leniolisib?
Common side effects reported in clinical trials for leniolisib include headache, nausea, diarrhea, and abdominal pain. Like many medications, it may also carry risks of more serious adverse events. Patients should discuss potential side effects and their individual risk factors with their healthcare provider [1].
What Are the Regulatory Approvals for Leniolisib?
Leniolisib has received regulatory approval in major markets for the treatment of APDS. For instance, it has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in patients with APDS [1].
Sources:
[1] https://www.biogen.com/en_us/news-room/press-releases/2023/biogen-announces-fda-approval-of-t-cells-for-the-treatment-of-activated-pi3k-delta-syndrome-APDS.html
[2] https://drugpatentwatch.com/